Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
TRPV4(Transient receptor potential cation channel subfamily V member 4) | 2 |
Target |
Mechanism TRPV4 agonists |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TNF-α inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date- |
Sponsor / Collaborator |
Start Date01 Dec 2003 |
Sponsor / Collaborator |
Start Date31 Aug 2003 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
RN-1734 ( TRPV4 ) | - | Preclinical |
RN-1747 ( TRPV4 ) | - | Preclinical |
REN-1654 ( TNF-α x p38 MAPK ) | Inflammatory Bowel Diseases More | Discontinued |
REN-214 | Pain More | Discontinued |
CPI 1714 ( Free radicals x MAPK ) | Rheumatoid Arthritis More | Discontinued |